Company news

Bristol-Myers Squibb Company news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

November 6, 2025

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

November 5, 2025

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

November 4, 2025

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

November 3, 2025

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

November 3, 2025

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

October 30, 2025

Global Initiative To Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients

October 29, 2025

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

October 27, 2025

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

October 25, 2025

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India

October 17, 2025

Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation

October 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform

October 14, 2025

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

October 13, 2025

Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives

October 10, 2025

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

October 10, 2025

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

October 10, 2025

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

October 1, 2025

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

October 1, 2025

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

Bristol Myers Squibb Commits to Veeva Vault CRM

September 22, 2025

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

September 16, 2025

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test

September 15, 2025

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

September 8, 2025

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025

September 2, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

August 29, 2025

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

August 25, 2025

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb

August 18, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

August 12, 2025

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

August 4, 2025

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

July 31, 2025

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

July 28, 2025

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

July 25, 2025

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July 21, 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

July 18, 2025

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

July 17, 2025

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025

Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)

July 7, 2025

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

June 26, 2025

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

June 16, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

June 12, 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

June 12, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

June 11, 2025

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

June 10, 2025

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

June 2, 2025

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

May 28, 2025

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

May 22, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 64 decks. Every deck is listed under its year.